Use
COPAXONE® is a prescription medicine that is used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Important Safety Information
Do not use COPAXONE® if you are allergic to glatiramer acetate or mannitol.

Please see Important Safety Information on Page 5, and read the Patient Information in the accompanying full Prescribing Information.
Doctor Discussion Guide

Helping people with relapsing MS make informed therapy decisions

Whether you are a current COPAXONE® (glatiramer acetate injection) patient or new to COPAXONE® therapy, it’s important to stay informed and take an active role in managing your prescription. Speaking with your doctor is always the first step. Use this guide to help you prepare questions and note your concerns before your appointment.

If you are currently taking COPAXONE®, consider asking the following questions at your next appointment:

How do I ensure my relapsing MS therapy is working as it should?

Notes
__________________________________________________________________________________________

How do I ensure I receive branded COPAXONE® with my next refill?

Notes
__________________________________________________________________________________________

If I am prescribed daily COPAXONE® 20 mg, can I switch to 3-times-a-week COPAXONE® 40 mg?

Notes
__________________________________________________________________________________________

Are there tools to help track and manage my COPAXONE® injections?

Notes
__________________________________________________________________________________________

Important Safety Information

Serious side effects may happen right after or within minutes after you inject COPAXONE® at any time during your course of treatment. Call your doctor right away if you have any of these immediate post-injection reaction symptoms including: redness to your cheeks or other parts of the body (flushing); chest pain; fast heart beat; anxiety; breathing problems or tightness in your throat; or swelling, rash, hives, or itching. If you have symptoms of an immediate post-injection reaction, do not give yourself more injections until a doctor tells you to.

Please see Important Safety Information on Page 5, and read the Patient Information in the accompanying full Prescribing Information.
Doctor Discussion Guide

How do I properly store my COPAXONE® (glatiramer acetate injection) syringes?

Notes

_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________

What kind of support am I eligible to receive during my COPAXONE® therapy?

Notes

_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________

Use the space below to note your own questions and concerns.

_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
Doctor Discussion Guide

If you are new to COPAXONE® (glatiramer acetate injection), consider asking the following questions:

☐ How is COPAXONE® administered? What if I have concerns about self-injection?
  Notes ____________________________________________

☐ How is COPAXONE® thought to work?
  Notes ____________________________________________

☐ How effective is COPAXONE® in reducing relapses?
  Notes ____________________________________________

☐ How safe is COPAXONE®?
  Notes ____________________________________________

☐ What side effects could I experience?
  Notes ____________________________________________

Important tips for new and current patients on COPAXONE® therapy

• Ask your doctor to specify language such as “Dispense as Written” (DAW) or “Brand Medically Necessary” on every COPAXONE® prescription, including refills, to ensure you receive your relapsing MS therapy as prescribed. Language may vary by state.
• Talk to your pharmacist and inspect the packaging to ensure you receive COPAXONE® as prescribed. Please visit COPAXONE.com for help properly identifying Teva’s COPAXONE®.
• Keep a detailed log of your treatment, symptoms, and side effects. Note any questions and concerns you’d like to share with your doctor as they occur.
• The COPAXONE iTracker® 2.0 for iPhone® or Android™ mobile app can help track your injection routine and assist with organizing notes to prepare for doctor appointments.
• Schedule follow-up visits as recommended or needed to manage your relapsing MS.
• Call Teva’s Shared Solutions® at 1-800-887-8100 or visit COPAXONE.com to learn about available support offerings.

Important Safety Information

You can have chest pain as part of an immediate post-injection reaction or by itself. This type of chest pain usually lasts a few minutes and can begin around 1 month after you start using COPAXONE®. Call your doctor right away if you have chest pain while using COPAXONE®.

Please see Important Safety Information on Page 5, and read the Patient Information in the accompanying full Prescribing Information.
Use

COPAXONE® (glatiramer acetate injection) is a prescription medicine that is used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Important Safety Information

Do not use COPAXONE® if you are allergic to glatiramer acetate or mannitol.

Serious side effects may happen right after or within minutes after you inject COPAXONE® at any time during your course of treatment. Call your doctor right away if you have any of these immediate post-injection reaction symptoms including: redness to your cheeks or other parts of the body (flushing); chest pain; fast heart beat; anxiety; breathing problems or tightness in your throat; or swelling, rash, hives, or itching. If you have symptoms of an immediate post-injection reaction, do not give yourself more injections until a doctor tells you to.

You can have chest pain as part of an immediate post-injection reaction or by itself. This type of chest pain usually lasts a few minutes and can begin around 1 month after you start using COPAXONE®. Call your doctor right away if you have chest pain while using COPAXONE®.

Damage to the fatty tissue just under your skin’s surface (lipoatrophy) and, rarely, death of your skin tissue (necrosis) can happen when you use COPAXONE®. Damage to the fatty tissue under your skin can cause a “dent” at the injection site that may not go away. You can reduce your chance of developing these problems by following your doctor’s instructions for how to use COPAXONE® and choosing a different injection area each time you use COPAXONE®.

Liver problems, including liver failure, can occur with COPAXONE®. Call your healthcare provider right away if you have symptoms, such as nausea, loss of appetite, tiredness, dark colored urine and pale stools, yellowing of your skin or the white part of your eye, bleeding more easily than normal, confusion, or sleepiness.

The most common side effects of COPAXONE® include redness, pain, swelling, itching, or a lump at the injection site; rash; shortness of breath; flushing; and chest pain.

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of COPAXONE®. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please read the Patient Information in the accompanying full Prescribing Information.
COPAXONE® (glatiramer acetate injection)

INDICATIONS AND USAGE COPAXONE is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

DOSAGE AND ADMINISTRATION

2.1 Recommended Dose COPAXONE is for subcutaneous use only. Do not administer intravenously. The dosing schedule depends on the product strength that is selected. The recommended doses are:

• COPAXONE 20 mg per mL: administer once per day
• COPAXONE 40 mg per mL: administer three times per week and at least 48 hours apart

2.2 Instructions for Use Remove one blister-packaged prefilled syringe from the refrigerated carton. Let the prefilled syringe stand at room temperature for 20 minutes to allow the solution to warm to room temperature. Visually inspect the syringe for particulate matter and discolored solution. The solution in the syringe should appear clear, colorless to slightly yellow. If particulate matter or discoloration is observed, discard the syringe. Areas for subcutaneous self-injection include arms, abdomen, hips, and thighs. The prefilled syringe is for single use only. Discard unused portions.

3 DOSAGE FORMS AND STRENGTHS

• Injection: 20 mg/mL in a single-dose prefilled syringe with a white plunger
• Injection: 40 mg/mL in a single-dose, prefilled syringe with a blue plunger

DOSAGE FORMS AND STRENGTHS

CONTRAINDICATIONS

Known hypersensitivity to glatiramer acetate or mannitol

WARNINGS AND PRECAUTIONS

• Immediate Post-Injection Reaction (flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and/or urticaria), may occur within seconds to minutes after injection and are generally transient and self-limiting

• Chest pain, usually transient

• Lipotrophy and skin necrosis may occur. Instruct patients in proper injection technique and to rotate injection sites

• COPAXONE can modify immune response

• Hepatic Injury; if signs or symptoms of hepatic dysfunction occur, consider discontinuing COPAXONE

ADVERSE REACTIONS

• In controlled studies of COPAXONE 20 mg/mL, most common adverse reactions ≥10% and ≥1.5 times higher than placebo were: injection site reactions, vasodilatation, rash, dyspnea, and chest pain

• In a controlled study of COPAXONE 40 mg/mL, most common adverse reactions ≥10% and ≥1.5 times higher than placebo were: injection site reactions

To report SUSPECTEDADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-468-0279 or FDA at 1-888-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 7/2020

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dose

2.2 Instructions for Use

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Immediate Post-Injection Reaction

5.2 Chest Pain

5.3 Lipotrophy and Skin Necrosis

5.4 Potential Effects on Immune Response

5.5 Hepatic Injury

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Postmarketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.3 Pediatric Use

8.4 Lactation

8.5 Geriatric Use

8.6 Use in Patients with Impaired Renal Function

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

15 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use COPAXONE® safely and effectively. See full prescribing information for COPAXONE.

COPAXONE® (glatiramer acetate injection), for subcutaneous use

Initial U.S. Approval: 1996

—RECENT MAJOR CHANGES—

Indications and Usage (1) 7/2019

Warnings and Precautions, Hepatic Injury (5.5) 7/2020

—INDICATIONS AND USAGE—

COPAXONE is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

—DOSE AND ADMINISTRATION—

• For subcutaneous injection only; doses are not interchangeable

• COPAXONE 20 mg/mL in a single-dose, prefilled syringe with a white plunger (3)

• COPAXONE 40 mg/mL three times per week (2.1)

• COPAXONE 20 mg/mL per day (2.1)

• For subcutaneous injection only; doses are not interchangeable (2.1)

• COPAXONE 40 mg/mL three times per week (2.1)

• Before use, allow the solution to warm to room temperature (2.2)

—DOSE FORMS AND STRENGTHS—

• Injection: 20 mg/mL in a single-dose prefilled syringe with a white plunger (3)

• Injection: 40 mg/mL in a single-dose, prefilled syringe with a blue plunger (3)

CONTRAINDICATIONS—

Known hypersensitivity to glatiramer acetate or mannitol

—WARNINGS AND PRECAUTIONS—

• Immediate Post-Injection Reaction (flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and/or urticaria), may occur within seconds to minutes after injection and are generally transient and self-limiting (5.1)

• Chest pain, usually transient (5.2)

• Lipotrophy and skin necrosis may occur. Instruct patients in proper injection technique and to rotate injection sites (5.3)

• COPAXONE can modify immune response (5.4)

• Hepatic Injury; if signs or symptoms of hepatic dysfunction occur, consider discontinuing COPAXONE (5.5)

ADVERSE REACTIONS—

• In controlled studies of COPAXONE 20 mg/mL, most common adverse reactions ≥10% and ≥1.5 times higher than placebo were: injection site reactions, vasodilatation, rash, dyspnea, and chest pain (6.1)

• In a controlled study of COPAXONE 40 mg/mL, most common adverse reactions ≥10% and ≥1.5 times higher than placebo were: injection site reactions (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-468-0279 or FDA at 1-888-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 7/2020
COPAXONE® (glatiramer acetate injection)

There is no evidence that COPAXONE does this, but there has not been a systematic evaluation of this risk. Because COPAXONE is an antigenic material, it is possible that its use may lead to the induction of host responses that are untoward, but systematic surveillance for these effects has not been undertaken.

Although COPAXONE is intended to minimize the autoimmune response to myelin, there is the possibility that continued alteration of cellular immunity due to chronic treatment with COPAXONE may result in untoward effects. Glatiramer acetate-reactive antibodies are formed in most patients receiving glatiramer acetate. Studies in both the rat and monkey have suggested that immune complexes are deposited in the renal glomeruli. Furthermore, in a controlled trial of 125 RMS patients given COPAXONE 20 mg per mL, subcutaneously every day for 2 years, serum IgG levels reached at least 3 times baseline values in 80% of patients by 3 months of initiation of treatment. By 12 months of treatment, however, 30% of patients still had IgG levels at least 3 times baseline values, and 90% had levels above baseline by 12 months. The antibodies are exclusively of the IgG subtype and predominantly of the IgG-1 subtype. No IgE type antibodies could be detected in any of the 94 sera tested; nevertheless, anaphylaxis can be associated with the administration of most any foreign substance, and therefore, this risk cannot be excluded.

5.5 Hepatic Injury

Cases of hepatic injury, some severe, including liver failure and hepatitis with jaundice, have been reported with COPAXONE. Hepatic injury has occurred from days to years after initiating treatment with COPAXONE. If signs or symptoms of liver dysfunction occur, consider discontinuation of COPAXONE.

6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:

- Immediate Post-Injection Reaction [see Warnings and Precautions (5.1)]
- Chest Pain [see Warnings and Precautions (5.2)]
- Lipoatrophy and Skin Necrosis [see Warnings and Precautions (5.3)]
- Potential Effects on Immune Response [see Warnings and Precautions (5.4)]
- Hepatic Injury [see Warnings and Precautions (5.5)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Incidence in Controlled Clinical Trials COPAXONE 20 mg per mL per day

Among 563 patients treated with COPAXONE in blinded placebo-controlled trials, approximately 5% of the patients discontinued treatment because of an adverse reaction. The adverse reactions most commonly associated with discontinuation were: injection site reactions, dyspnea, urticaria, vasodilatation, and hypersensitivity. The most common adverse reactions were: injection site reactions, vasodilatation, rash, dyspnea, and chest pain.

Table 1 lists signs and symptoms that occurred in at least 2% of patients treated with COPAXONE 20 mg per mL in the placebo-controlled trials. These signs and symptoms were numerically more common in patients treated with COPAXONE than in patients treated with placebo. Adverse reactions were usually mild in intensity.

Table 1: Adverse Reactions in Controlled Clinical Trials with an Incidence ≥2% of Patients and More Frequent with COPAXONE (20 mg per mL Daily) than with Placebo

<table>
<thead>
<tr>
<th>Category</th>
<th>COPAXONE 20 mg/mL (n=563) %</th>
<th>Placebo (n=564) %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood And Lymphatic System Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>Cardiac Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Palpitations</td>
<td>9</td>
<td>4</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Eye Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye Disorder</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Diplopia</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>15</td>
<td>11</td>
</tr>
<tr>
<td>Vomiting</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>Dysphagia</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>General Disorders And Administration Site Conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injection Site Erythema</td>
<td>43</td>
<td>10</td>
</tr>
<tr>
<td>Injection Site Pain</td>
<td>40</td>
<td>20</td>
</tr>
<tr>
<td>Injection Site Pruritus</td>
<td>27</td>
<td>4</td>
</tr>
<tr>
<td>Injection Site Mass</td>
<td>26</td>
<td>6</td>
</tr>
<tr>
<td>Asthenia</td>
<td>22</td>
<td>21</td>
</tr>
<tr>
<td>Pain</td>
<td>20</td>
<td>17</td>
</tr>
<tr>
<td>Injection Site Edema</td>
<td>19</td>
<td>4</td>
</tr>
<tr>
<td>Chest Pain</td>
<td>13</td>
<td>6</td>
</tr>
<tr>
<td>Injection Site Inflammation</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>Edema</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>Injection Site Reaction</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>6</td>
<td>5</td>
</tr>
</tbody>
</table>

Immune System Disorders

- Hypersensitivity 3 2

Infections And Infestations

- Infection 30 28
- Influenza 14 13
- Rhinitis 7 5
- Bronchitis 6 5
- Gastroenteritis 6 4
- Vaginal Candidiasis 4 2

Metabolism And Nutrition Disorders

- Weight Increased 3 1

Musculoskeletal And Connective Tissue Disorders

- Back Pain 12 10

Neoplasms Benign, Malignant And Unspecified (Incl Cysts And Polyps)

- Benign Neoplasm of Skin And Appendages 2 1

Nervous System Disorders

- Tremor 4 2
- Migraine 4 2
- Syncope 3 2
- Speech Disorder 2 1

Psychiatric Disorders

- Anxiety 13 10
- Nervousness 2 1

Renal And Urinary Disorders

- Micturition Urgency 5 4

Respiratory, Thoracic And Mediastinal Disorders

- Dyspnea 14 4
- Cough 6 5
- Laryngospasm 2 1

Skin And Subcutaneous Tissue Disorders

- Rash 19 11
- Hyperhidrosis 7 5
- Pruritus 5 4
- Urticaria 3 1
- Skin Disorder 3 1

Vascular Disorders

- Vasodilatation 20 5

* Injection site atrophy comprises terms relating to localized lipoatrophy at injection site.

Adverse reactions which occurred only in 4 to 5 more subjects in the COPAXONE group than in the placebo group (less than 1% difference), but for which a relationship to COPAXONE could not be excluded, were arthralgia and herpes simplex.

Laboratory analyses were performed on all patients participating in the clinical program for COPAXONE. Clinically-significant laboratory values for hematology, chemistry, and urinalysis were similar for both COPAXONE and placebo groups in blinded clinical trials. In controlled trials one patient discontinued treatment due to thrombocytopenia (16 x10⁹/L), which resolved after discontinuation of treatment. Data on adverse reactions occurring in the controlled clinical trials of COPAXONE 20 mg per mL were analyzed to evaluate differences based on sex. No clinically-significant differences were identified. Ninety-six percent of patients in these clinical trials were Caucasian. The majority of patients treated with COPAXONE were between the ages of 18 and 45. Consequently, data are inadequate to perform an analysis of the adverse reaction incidence related to clinically-relevant age subgroups.

Other Adverse Reactions

In the paragraphs that follow, the frequencies of less commonly reported adverse clinical reactions are presented. Because the reports include reactions observed in open and uncontrolled premarketing studies (n=979), the role of COPAXONE in their causation cannot be reliably determined. Furthermore, variability associated with adverse reaction reporting, the terminology used to describe adverse reactions, etc., limit the value of the quantitative frequency estimates provided. Reaction frequencies are calculated as the number of patients who used COPAXONE and reported a reaction divided by the total number of patients exposed to COPAXONE. All reported reactions are included except those already listed in the previous table, those too general to be informative, and those not reasonably associated with the use of the drug. Reactions are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: Frequent adverse reactions are defined as those occurring in at least 1/100 patients and infrequent adverse reactions are those occurring in 1/100 to 1/1,000 patients.
COPAXONE® (glatiramer acetate injection)

Table 2: Adverse Reactions in a Controlled Clinical Trial with an Incidence

<table>
<thead>
<tr>
<th>Condition</th>
<th>COPAXONE 40 mg/mL (n=943)</th>
<th>Placebo (n=461)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections And Infestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td>Respiratory Tract Infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Respiratory, Thoracic and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mediastinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnea</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasodilatation</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Skin And Subcutaneous Tissue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythema</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Rash</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

No new adverse reactions appeared in subjects treated with COPAXONE 40 mg/mL three times per week as compared to subjects treated with COPAXONE 20 mg per mL per day in clinical trials and during postmarketing experience. Data on adverse reactions occurring in the controlled clinical trial of COPAXONE 40 mg per mL were analyzed to evaluate differences based on sex. No clinically significant differences were identified. Ninety-eight percent of patients in this clinical trial were Caucasian and the majority were between the ages of 18 and 50. Consequently, data are inadequate to perform an analysis of the adverse reaction incidence related to clinically-relevant age groups. 6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of COPAXONE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Body as a Whole: sepsis; SLE syndrome; hydrocephalus; enlarged abdomen; allergic reaction; anaphylactoid reaction Cardiovascular System: thrombosis; peripheral vascular disease; pericardial effusion; myocardial infarct; deep thrombophlebitis; coronary occlusion; congestive heart failure; cardiomyopathy; cardiomegaly; arrhythmia; angina pectoris Digestive System: tongue edema; stomach ulcer; hemorrhage; eructation Hemic and Lympathic System: thrombocytopenia; lymphoma-like reaction; acute leukemia Hepatobiliary Disorders: cholelithiasis; liver function abnormality; cirrhosis of the liver; hepatitis; hepatic injury [see Warnings and Precautions (5.5)] Metabolic and Nutritional Disorders: hypercholesterolemia Musculoskeletal System: rheumatoid arthritis; generalized spasm Nervous System: myelitis; meningitis; CNS neoplasm; cerebrovascular accident; brain edema; abnormal dreams; aphasia; convulsion; neuralgia Respiratory System: pulmonary embolus; pleural effusion; carcinoma of lung Special Senses: glaucoma; blindness Urogenital System: urogenital neoplasm; urine abnormality; ovarian carcinoma; nephrosis; kidney failure; breast carcinoma; bladder carcinoma; urinary frequency 7.5 Drug Interactions

Interactions between COPAXONE and other drugs have not been fully evaluated. Results from existing clinical trials do not suggest any significant interactions of COPAXONE with therapies commonly used in MS patients, including the concurrent use of corticosteroids for up to 28 days. COPAXONE has not been formally evaluated in combination with interferon beta. 8. USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Available human data on the use of COPAXONE in pregnant women are not sufficient to support conclusions about drug-associated risk for major birth defects and miscarriage. Administration of glatiramer acetate by subcutaneous injection to pregnant rats and rabbits resulted in no adverse effects on embryofetal or offspring development [see Data]. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Human Data

There are no adequate and well-controlled studies of COPAXONE in pregnant women. The available postmarketing reports, case series, and small cohort studies do not provide sufficient information to support conclusions about drug-associated risk for major birth defects and miscarriage.

Animal Data

In rats or rabbits receiving glatiramer acetate by subcutaneous injection during the period of organogenesis, no adverse effects on embryofetal development were observed at doses up to 37.5 mg/kg/day (18 and 36 times, respectively, the therapeutic human dose of 20 mg/day on a mg/m² basis). In rats receiving subcutaneous glatiramer acetate at doses of up to 36 mg/kg from day 15 of pregnancy throughout lactation, no significant effects on delivery or on offspring growth and development were observed. 8.2 Lactation

Risk Summary

There are no data on the presence of glatiramer acetate in human milk; the effects on breastfed infants, or the effects on milk production.
COPAXONE® (glatiramer acetate injection)

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for COPAXONE and any potential adverse effects on the breastfed infant from COPAXONE or from the underlying maternal condition.

8.4 Pediatric Use

The safety and effectiveness of COPAXONE have not been established in patients under 18 years of age.

8.5 Geriatric Use

COPAXONE has not been studied in elderly patients.

8.6 Use in Patients with Impaired Renal Function

The pharmacokinetics of glatiramer acetate in patients with impaired renal function have not been determined.

11 DESCRIPTION

Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000 – 9,000 daltons. Glatiramer acetate is identified by CAS - 147245-92-9.

COPAXONE is a clear, colorless to slightly yellow, sterile, nonpyrogenic solution for subcutaneous injection. Each 1 mL of COPAXONE solution contains 20 mg or 40 mg of glatiramer acetate and the following inactive ingredient: 40 mg of mannitol. The pH of the solutions is approximately 5.5 to 7.0. The biological activity of glatiramer acetate is determined by its ability to block the induction of experimental autoimmune encephalomyelitis (EAE) in mice.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatiramer acetate is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS. This hypothesis is supported by findings of studies that have been carried out to explore the pathogenesis of experimental autoimmune encephalomyelitis, a condition induced in animals through immunization against central nervous system derived material containing myelin and often used as an experimental animal model of MS. Studies in animals and in vitro systems suggest that upon its administration, glatiramer acetate-specific suppressor T-cells are induced and activated in the periphery.

Because glatiramer acetate can modify immune functions, concerns exist about its potential to alter naturally-occurring immune responses. There is no evidence that glatiramer acetate does this, but this has not been systematically evaluated [see Warnings and Precautions (5.4)].

12.2 Pharmacokinetics

Results obtained in pharmacokinetic studies performed in humans (healthy volunteers) and animals support that a substantial fraction of the therapeutic dose delivered to patients subcutaneously is hydrolyzed locally. Larger fragments of glatiramer acetate can be recognized by glatiramer acetate-reactive antibodies. Some fraction of the injected material, either intact or partially hydrolyzed, is presumed to enter the lymphatic circulation, enabling it to reach regional lymph nodes, and some may enter the systemic circulation intact.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

In a 2-year carcinogenicity study, mice were administered up to 60 mg/kg/day glatiramer acetate by subcutaneous injection (up to 15 times the human therapeutic dose on a mg/m² basis). No increase in systemic neoplasms was observed. In males receiving the 60-mg/kg/day dose, there was an increased incidence of fibrosarcomas at the injection sites. These sarcomas were associated with skin damage precipitated by repetitive injections of an irritant over a limited skin area.

In a 2-year carcinogenicity study, rats were administered up to 30 mg/kg/day glatiramer acetate by subcutaneous injection (up to 15 times the human therapeutic dose on a mg/m² basis). No increase in neoplasms was observed.

Mutagenesis

Glatiramer acetate was not mutagenic in in vitro (Ames test, mouse lymphoma tk) assays. Glatiramer acetate was clastogenic in two separate in vitro chromosomal aberration assays in cultured human lymphocytes but not clastogenic in an in vivo mouse bone marrow micronucleus assay.

Impairment of Fertility

When glatiramer acetate was administered by subcutaneous injection prior to and during mating (males and females) and throughout gestation and lactation (females) at doses up to 36 mg/kg/day (18 times the human therapeutic dose on a mg/m² basis) no adverse effects were observed on reproductive or developmental parameters.
Patients treated with COPAXONE demonstrated fewer new T2 lesions at the last observation (rate ratio 0.41; confidence interval 0.28 to 0.59; \( p < 0.0001 \)). Additionally, baseline-adjusted T2 lesion volume at the last observation was lower for patients treated with COPAXONE (ratio of 0.89; confidence interval 0.84 to 0.94; \( p = 0.0001 \)).

Study 4 was a multinational study in which MRI parameters were used both as primary and secondary endpoints. A total of 239 patients with RRMS (COPAXONE: \( n = 119 \); and placebo: \( n = 120 \) ) were randomized. Inclusion criteria were similar to those in the second study with the additional criterion that patients had to have at least one Gd-enhancing lesion on the screening MRI. The patients were treated in a double-blind manner for nine months, during which they underwent monthly MRI scanning. The primary endpoint for the double-blind phase was the total cumulative number of T1 Gd-enhancing lesions over the nine months. Table 5 summarizes the results for the primary outcome measure monitored during the trial for the intent-to-treat cohort.

**Table 5: Study 4 MRI Results**

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>COPAXONE 40 mg/mL (n=494)</th>
<th>Placebo (n=461)</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Endpoints</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of confirmed relapses</td>
<td>0.905</td>
<td>0.505</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Relative risk reduction</td>
<td>0.505</td>
<td>0.505</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>MRI Endpoints</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cumulative number of new or enlarging T2 lesions at Months 6 and 12</td>
<td>3.650</td>
<td>5.592</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Relative risk reduction</td>
<td>0.905</td>
<td>0.505</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Adjusted Mean Estimates</td>
<td>0.505</td>
<td>0.505</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

**Figure 2 displays the results of the primary outcome on a monthly basis.**

**Figure 2: Median Cumulative Number of Gd-Enhancing Lesions**

COPAXONE 40 mg per mL three times per week

Study 5 was a double-blind, placebo-controlled, multinational study with a total of 1404 patients with RRMS randomized in a 2:1 ratio to receive either COPAXONE 40 mg per mL (n=943) or placebo (n=461) three times a week for 12 months. Patients had a median of 2 relapses in the 2 years prior to screening and had not received any interferon-beta for at least 2 months prior to screening. Baseline EDSS scores ranged from 0 to 5.5 with a median of 2.5. Neurological evaluations were performed at baseline, every three months, and at unscheduled visits for suspected relapse or early termination. MRI was performed at baseline, months 6 and 12, or early termination. A total of 91% of those assigned to COPAXONE and 95% of those assigned to placebo completed treatment at 12 months.
COPAXONE® (glatiramer acetate injection)

Storage Conditions
Advise patients that the recommended storage condition for COPAXONE is refrigeration at 36°F to 46°F (2°C to 8°C). If needed, the patient may store COPAXONE at room temperature, 59°F to 86°F (15°C to 30°C), for up to one month, but refrigeration is preferred. COPAXONE should not be exposed to higher temperatures or intense light. Do not freeze COPAXONE.

Marketed by: Teva Neuroscience, Inc., Parsippany, NJ 07054
Distributed by: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054
©2020 Teva Neuroscience, Inc.
COP-007

Patient Information
COPAXONE (co-PAX-own)
(glattiramer acetate injection)
for subcutaneous use

Read this Patient Information before you start using COPAXONE and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.

What is COPAXONE?
COPAXONE is a prescription medicine that is used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is not known if COPAXONE is safe and effective in children under 18 years of age.

Who should not use COPAXONE?
• Do not use COPAXONE if you are allergic to glatiramer acetate, mannitol or any of the ingredients in COPAXONE. See the end of this leaflet for a complete list of the ingredients in COPAXONE.

What should I tell my doctor before using COPAXONE?
Before you use COPAXONE, tell your doctor if you:
• are pregnant or plan to become pregnant. It is not known if COPAXONE will harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if COPAXONE passes into your breast milk. Talk to your doctor about the best way to feed your baby while using COPAXONE.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
COPAXONE may affect the way other medicines work, and other medicines may affect how COPAXONE works.
Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist when you get a new medicine.

How should I use COPAXONE?
• For detailed instructions, see the Instructions for Use at the end of this leaflet for complete information on how to use COPAXONE.
• Your doctor will tell you how much COPAXONE to use and when to use it.
• COPAXONE is given by injection under your skin (subcutaneously).
• Use COPAXONE exactly as your doctor tells you to use it.
• Since every body type is different, talk with your doctor about the injection areas that are best for you.
• You should receive your first dose of COPAXONE with a doctor or nurse present. This might be at your doctor’s office or with a visiting home health nurse who will teach you how to give your COPAXONE injections.

What are the possible side effects of COPAXONE?
COPAXONE may cause serious side effects, including:
• Immediate Post-Injection Reactions. Serious side effects may happen right after or within minutes after you inject COPAXONE at any time during your course of treatment. Call your doctor right away if you have any of these immediate post-injection reaction symptoms including:
  • redness to your cheeks or other parts of the body (flushing)
  • chest pain
  • fast heart beat
  • anxiety
  • breathing problems or tightness in your throat
  • swelling, rash, hives, or itching
If you have symptoms of an immediate post-injection reaction, do not give yourself more injections until a doctor tells you to.
• Chest Pain. You can have chest pain as part of an immediate post-injection reaction or by itself. This type of chest pain usually lasts a few minutes and can begin around 1 month after you start using COPAXONE. Call your doctor right away if you have chest pain while using COPAXONE.
• Damage to your skin. Damage to the fatty tissue just under your skin’s surface (lipatrophy) and, rarely, death of your skin tissue (necrosis) can happen when you use COPAXONE. Damage to the fatty tissue under your skin can cause a “dent” at the injection site that may not go away. You can reduce your chance of developing these problems by:
  • following your doctor’s instructions for how to use COPAXONE
  • choosing a different injection area each time you use COPAXONE. See Step 4 in the Instructions for Use, “Choose your injection area”.
• Liver problems. Liver problems, including liver failure, can occur with COPAXONE. Call your healthcare provider right away if you have symptoms, such as:
  • nausea
  • loss of appetite
  • tiredness
  • dark colored urine and pale stools
  • yellowing of your skin or the white part of your eye
  • bleeding more easily than normal
  • confusion
  • sleepiness
The most common side effects of COPAXONE include:
• skin problems at your injection site including:
  • redness
  • pain
  • swelling
  • itching
  • lumps
• rash
• shortness of breath
• flushing (vasodilation)
Tell your doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of COPAXONE. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store COPAXONE?
• Store COPAXONE in the refrigerator between 36°F to 46°F (2°C to 8°C).
• When you are not able to refrigerate COPAXONE, you may store it for up to 1 month at room temperature between 59°F to 86°F (15°C to 30°C).
• Protect COPAXONE from light or high temperature.
• Do not freeze COPAXONE syringes. If a syringe freezes, throw it away in a sharps disposal container. See Step 13 in the Instructions for Use, “Dispose of your needles and syringes”.
Keep COPAXONE and all medicines out of the reach of children.
Instructions for Use
COPAXONE (co-PAX-own) (glatiramer acetate injection) for subcutaneous use

For subcutaneous injection only.
Do not inject COPAXONE in your veins (intravenously).
Do not re-use your COPAXONE prefilled syringes.
Do not share your COPAXONE prefilled syringes with another person.
You may give another person an infection or get an infection from them.
You should receive your first dose of COPAXONE with a doctor or nurse present. This might be at your doctor’s office or with a visiting home health nurse who will show you how to give your own injections.
COPAXONE comes in either a 20 mg Prefilled Syringe with needle attached or a 40 mg Prefilled Syringe with needle attached. How often a dose is given depends on the product strength that is prescribed. Your doctor will prescribe the correct dose for you.

Instructions for Using Your COPAXONE 20 mg Prefilled Syringe:
• COPAXONE 20 mg is injected 1 time each day, in the fatty layer under your skin (subcutaneously).
• Each COPAXONE 20 mg prefilled syringe is for single use (1 time use) only.
• The COPAXONE 20 mg dose is packaged in boxes of 30 prefilled syringes with needles attached. COPAXONE 20 mg prefilled syringes have white plungers.

Instructions for Using Your COPAXONE 40 mg Prefilled Syringe:
• COPAXONE 40 mg is injected 3 times each week, in the fatty layer under your skin (subcutaneously).
• COPAXONE 40 mg should be given on the same 3 days each week, if possible for example, Monday, Wednesday, and Friday. Give your COPAXONE injections at least 48 hours (2 days) apart.
• Each COPAXONE 40 mg prefilled syringe is for single use (1 time use) only.
• The COPAXONE 40 mg dose is packaged in boxes of 12 prefilled syringes with needles attached. COPAXONE 40 mg prefilled syringes have blue plungers.

How do I inject COPAXONE?
Step 1: Gather the supplies you will need to inject COPAXONE. See Figure A.
• 1 blister pack with a COPAXONE Prefilled Syringe with needle attached
• Alcohol wipe (not supplied)
• Dry cotton ball (not supplied)

Step 2: Remove only 1 blister pack from the COPAXONE prefilled syringe carton. See Figure B.
• Place the supplies you will need on a clean, flat surface in a well-lit area.
• After you remove 1 blister pack from the carton, keep all unused syringes in the carton and store them in the refrigerator.
• Let the blister pack, with the syringe inside, warm to room temperature for about 20 minutes.
• Wash your hands. Be careful not to touch your face or hair after washing your hands.

Step 3: Look closely at your COPAXONE prefilled syringe.
• There may be small air bubbles in the syringe. Do not try to push the air bubble from the syringe before giving your injection so you do not lose any medicine.
• Check the liquid medicine in the syringe before you give your injection. The liquid in the syringe should look clear, colorless, and may look slightly yellow. If the liquid is cloudy or contains any particles, do not use the syringe and throw it away in a sharps disposal container. See Step 13 below, “Dispose of your needles and syringes.”

Step 4: Choose your injection area. See Figure C.
See the injection areas you should use on your body. Talk with your doctor about the injection areas that are best for you.
• The possible injection areas on your body include (See Figure C):
  ◦ your stomach area (abdomen) around the belly button
  ◦ the back of your upper arms
  ◦ upper hips (below your waist)
  ◦ your thighs (above your knees)
For each COPAXONE dose, choose a different injection area from 1 of the areas shown above. See Figure C.

Do not stick the needle in the same place (site) more than 1 time each week. Each injection area contains multiple injection sites for you to choose from. Avoid injecting in the same site over and over again.

Keep a record of the sites where you give your injection each day so you will remember where you already injected.

- There are some injection areas on your body that are hard to reach (like the back of your arm). You may need help from someone who has been instructed on how to give your injection if you cannot reach certain injection areas.
- Do not inject in sites where the skin has scarring or “dents”. Using scarred or dented skin for your injections may make your skin worse.

Clean your injection site.

- Clean the injection site using the alcohol wipe and allow your skin to air dry. See Figure D.

Pick up the syringe with 1 hand and hold it like a pencil. Remove the needle cover with your other hand and set it aside. See Figure E.

Pinch about a 2 inch fold of skin between your thumb and index finger. See Figure F.

Giving your injection:

- Rest the heel of your hand holding the syringe against your skin at the injection site. Insert the needle at a 90 degree angle straight into your skin. See Figure G.

- When the needle is all the way into your skin, release the fold of skin. See Figure H.

Give your COPAXONE injection.

To inject the medicine, hold the syringe steady and slowly push down the plunger. See Figure I.

Remove the needle.

After you have injected all of the medicine, pull the needle straight out. See Figure J.

Use a clean, dry cotton ball to gently press on the injection site for a few seconds. Do not rub the injection site or re-use the needle or syringe. See Figure K.
**Step 13:** Dispose of your needles and syringes.

- Put your used needles and syringes in a FDA-cleared sharps disposal container right away after use. **Do not throw away (dispose of) loose needles and syringes in your household trash.**
- If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
  - made of a heavy-duty plastic,
  - can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
  - upright and stable during use,
  - leak-resistant, and
  - properly labeled to warn of hazardous waste inside the container.
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal.
- Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.